On the morning of July 18, 2019, Yunnan Longjin Careyou Pharmaceutical Co., Ltd. signed a generic drug research and development cooperation agreement with Intelliscend Pharmaceutical Research and Development Company and CBC India. This is the first research and development contract signed by Longjin Careyou since its layout in the field of characteristic generic drugs, marking the key step of Longjin Pharmaceutical research and development in the field of generic drugs, and also means that Longjin Pharmaceutical internationalization has taken a key step.

Longjin Careyou as important layout features of generic drugs, will focus on heart cerebrovascular disease areas. Intelliscend was selected as the first project partner from five potential partners on a recent tour of the company's generics-medicine team, which has made several trips to India. After signing the agreement, both parties will carry out cooperation according to the strategic layout and product pipeline layout of Longjin.

Longjin Careyou hope that all of the advantages with generics sector in China, grasping the opportunity, with the help of India Intelliscend and CBC company advantage, through mode innovation, change for generics industry in China, brings the Gospel for Chinese patients.

Mr. Fan Xianhe, chairman of Longjin Pharmaceutical, said that investment in the research and development of characteristic generic drugs is the key step of the company's strategy and an important measure of the company's transformation. The company will invest superior resources to support the generic drug sector, and also needs the full support of various partners to Longjin Kangyou. Indian generics market mature, Intelliscend company has rich experience in research and development of generic drugs, Dr Roy has experienced in r&d internationalization, the internationalization of CBC layout can provide more resources, the tripartite cooperation can bring new vitality to longjin pharmaceutical generics sector.

Longjin Careyou chairman li-juan fan, argues ms generic drugs research and development the road full of hardships, but will not waver Long Jinkang bless to apply better technology, to provide human with faster curative effect, quality control, the mission of affordable medicines and beginner's mind. Company core competitiveness in the field of pharmaceutical is enough to support Long Jinkang on development in the field of generic drugs, the team will unswervingly support the company's strategic decision-making and development direction.

Dr. Sunilendu Bhushan Roy, founder, CEO and Chief scientist of Intelliscend, delivered a speech at the signing ceremony, hoping to share his 30 years of experience and technology in the pharmaceutical field with Chinese pharmaceutical companies to provide support for the internationalization of Chinese pharmaceutical companies. Dr. Roy was previously President of Sandoz India Technology Center, where he was highly effective in the research and development of anti-inflammatory drugs and digestive system drugs.

Mr. Vivek Kaushal, Senior General Manager of CBC India, and Mr. Wang Hong, General Manager of CBC Shanghai, both gave speeches on the stage and gave high evaluation and best wishes for the project cooperation. CBC India will rely on its business resources in India and China to find API suppliers for cooperation projects, and use this as an opportunity to establish long-term cooperative relationships, jointly cultivate R&D professional teams, seek more business opportunities in China, and assist Chinese pharmaceutical companies to achieve international development.

The core members of the cooperation parties and the representatives of Longjinhui shareholders witnessed the signing of the three parties on the spot, and finally took a group photo as a souvenir. The signing ceremony was successfully completed.